Skip to content

Why clinicians should lead hospitals, according to Prof. Amanda Goodall
China NMPA approves pirtobrutinib in relapsed/refractory CLL/SLL
FDA accepts NDA for iberdomide in relapsed/refractory myeloma
Drs. Zhang and Bona discuss financial toxicity in pediatric oncology
FDA accepts NDA for tirabrutinib in relapsed or refractory PCNSL

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Susan O’Brien, MD

Cellular Therapy

Susan O’Brien, MD

Leukemia

Susan O’Brien, MD

Lymphoma

Susan O’Brien, MD

Multiple Myeloma

Susan O’Brien, MD

Myelodysplastic Syndromes

Susan O’Brien, MD

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

March 10, 2026

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

SOHO Insider Susan O’Brien, MD

Susan O’Brien, MD

by sohonews
October 16, 2024
0 Comments
Less than a minute
806 Views
1 year ago

Share This Post:

Facebook Twitter Pinterest Whatsapp Cloud StumbleUpon Print Share via Email

Related Post

SOHO Insider podcast for feature view

Cellular Therapy, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, News

Why clinicians should lead hospitals, according to Prof. Amanda

March 10, 2026

Chinese flag

Leukemia, Chronic Lymphocytic Leukemia, Lymphoma, Indolent B-Cell Lymphomas, News

China NMPA approves pirtobrutinib in relapsed/refractory CLL/SLL

March 10, 2026

FDA stamp on white paper

Cellular Therapy, Multiple Myeloma, News

FDA accepts NDA for iberdomide in relapsed/refractory myeloma

March 9, 2026

American Dollars in Focus. Benjamin Franklin One Hundred Dollars Banknotes. Dollar Trading.

ASH 2025, Leukemia, Acute Lymphoblastic Leukemia, News

Drs. Zhang and Bona discuss financial toxicity in pediatric

March 9, 2026

FDA Green light

Lymphoma, Aggressive B-Cell Lymphomas, News

FDA accepts NDA for tirabrutinib in relapsed or refractory

March 8, 2026

SOHO UK, Leukemia, Acute Myeloid Leukemia, News

New therapies push UK registries into central role

March 7, 2026

Top Categories

Cellular Therapy

54

Leukemia

89

Lymphoma

95

Multiple Myeloma

80

Myelodysplastic Syndromes

29

Myeloproliferative Neoplasms

19

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Susan O’Brien, MD

Cellular Therapy

Susan O’Brien, MD

Leukemia

Susan O’Brien, MD

Lymphoma

Susan O’Brien, MD

Multiple Myeloma

Susan O’Brien, MD

Myelodysplastic Syndromes

Susan O’Brien, MD

Myeloproliferative Neoplasms

Subscribe

Recent Posts

SOHO Insider podcast for feature view

Why clinicians should lead hospitals, according to Prof. Amanda Goodall

Chinese flag

China NMPA approves pirtobrutinib in relapsed/refractory CLL/SLL

FDA stamp on white paper

FDA accepts NDA for iberdomide in relapsed/refractory myeloma

Copyright © 2026 Society of Hematologic Oncology, All rights reserved.